ES2601137T3 - Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido - Google Patents

Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido Download PDF

Info

Publication number
ES2601137T3
ES2601137T3 ES15382164.0T ES15382164T ES2601137T3 ES 2601137 T3 ES2601137 T3 ES 2601137T3 ES 15382164 T ES15382164 T ES 15382164T ES 2601137 T3 ES2601137 T3 ES 2601137T3
Authority
ES
Spain
Prior art keywords
dissolved oxygen
oxygen level
human albumin
preparation procedure
reduced dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15382164.0T
Other languages
English (en)
Inventor
Juan Ignacio Jorquera Nieto
Ana Maria Ortiz Fernández
Montserrat Costa Rierola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2601137(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols SA filed Critical Grifols SA
Application granted granted Critical
Publication of ES2601137T3 publication Critical patent/ES2601137T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procedimiento de preparación de una solución de albúmina humana caracterizado porque comprende una etapa de reducción del oxígeno disuelto en dicha solución de albúmina en la que el nivel de oxígeno se reduce hasta una concentración igual o menor que 0,5 ppm.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES15382164.0T 2014-05-29 2015-04-01 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido Active ES2601137T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430824 2014-05-29
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Publications (1)

Publication Number Publication Date
ES2601137T3 true ES2601137T3 (es) 2017-02-14

Family

ID=52003454

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430824A Expired - Fee Related ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES15382164.0T Active ES2601137T3 (es) 2014-05-29 2015-04-01 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES201430824A Expired - Fee Related ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Country Status (22)

Country Link
US (1) US10350274B2 (es)
EP (1) EP2952203B9 (es)
JP (3) JP2015224251A (es)
KR (1) KR101960729B1 (es)
CN (1) CN105315362B (es)
AR (1) AR100618A1 (es)
AU (1) AU2015202413B2 (es)
BR (1) BR102015012091A8 (es)
CA (1) CA2890642C (es)
CL (1) CL2015001446A1 (es)
ES (2) ES2524516B1 (es)
HU (1) HUE031823T2 (es)
IL (1) IL238898B (es)
MX (1) MX362869B (es)
MY (1) MY171771A (es)
NZ (1) NZ708537A (es)
PL (1) PL2952203T3 (es)
PT (1) PT2952203T (es)
RU (1) RU2657578C2 (es)
SG (1) SG10201504137PA (es)
TW (1) TWI607018B (es)
ZA (1) ZA201503539B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
WO2017189919A2 (en) 2016-04-28 2017-11-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
AU2017312722B2 (en) 2016-08-18 2020-01-02 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
MX2019012795A (es) 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
DE202019006065U1 (de) 2018-07-20 2024-06-24 Alkahest, Inc. Dosierungsregime zur Behandlung kognitiver und motorischer Störungen mit Blutplasma und Blutplasmaprodukten
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法
CN118166053A (zh) * 2024-03-15 2024-06-11 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE60234142D1 (de) * 2001-03-27 2009-12-10 Nipro Corp Albuminlösung enthaltender Kunststoffbehälter
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
WO2003002139A1 (fr) * 2001-06-29 2003-01-09 Asahi Kasei Kabushiki Kaisha Procede permettant d'ameliorer la stabilite de la preparation de proteines
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
ES2270245T3 (es) * 2003-08-28 2007-04-01 Nipro Corporation Vehiculo de oxigeno artificial y su metodo de produccion.
RS52459B (en) * 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. STABILIZED GLUCOCEREBROSIDASE COMPOSITIONS
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Also Published As

Publication number Publication date
RU2015118453A (ru) 2016-12-10
ZA201503539B (en) 2017-01-25
JP2015224251A (ja) 2015-12-14
US10350274B2 (en) 2019-07-16
HUE031823T2 (en) 2017-08-28
US20170000855A9 (en) 2017-01-05
AU2015202413A1 (en) 2015-12-17
MX2015006407A (es) 2015-11-30
US20150343025A1 (en) 2015-12-03
KR101960729B1 (ko) 2019-03-21
ES2524516B1 (es) 2015-03-31
TW201544510A (zh) 2015-12-01
AU2015202413B2 (en) 2017-08-31
TWI607018B (zh) 2017-12-01
JP2018115210A (ja) 2018-07-26
RU2657578C2 (ru) 2018-06-14
EP2952203A1 (en) 2015-12-09
MY171771A (en) 2019-10-29
CL2015001446A1 (es) 2016-05-13
JP2020111614A (ja) 2020-07-27
CN105315362B (zh) 2019-10-25
CA2890642A1 (en) 2015-11-29
ES2524516A1 (es) 2014-12-09
PT2952203T (pt) 2016-11-23
CA2890642C (en) 2019-02-12
EP2952203B9 (en) 2018-03-14
CN105315362A (zh) 2016-02-10
KR20160024348A (ko) 2016-03-04
IL238898B (en) 2018-01-31
BR102015012091A8 (pt) 2021-03-16
AR100618A1 (es) 2016-10-19
MX362869B (es) 2019-02-20
PL2952203T3 (pl) 2017-02-28
EP2952203B1 (en) 2016-10-26
NZ708537A (en) 2017-06-30
BR102015012091A2 (pt) 2016-01-05
SG10201504137PA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
ES2601137T3 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2663817T3 (es) Proceso para producir una disolución inyectable estable de noradrenalina a baja concentración
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
CL2016002243A1 (es) Un método, dispositivo y sistema para desplegar tendencias y variación en un grupode datos fisiológicos.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
EA202091989A1 (ru) Способы лечения язвенного колита
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
EA201791174A1 (ru) Антимикотическое соединение
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
CY1120187T1 (el) Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης
UY36150A (es) Derivados de naftiridinadiona
CL2017000132A1 (es) Proceso de acetilación de la madera
ECSP17021465A (es) Formulación que comprende glicopirrolato, método y aparato
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
ES2528394B1 (es) Procedimiento de hidrólisis de biomasa lignocelulósica